Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7993831rdf:typepubmed:Citationlld:pubmed
pubmed-article:7993831lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0042963lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0011777lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0025853lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0061863lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C1708528lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7993831lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:7993831pubmed:issue7lld:pubmed
pubmed-article:7993831pubmed:dateCreated1995-1-13lld:pubmed
pubmed-article:7993831pubmed:abstractTextThree anti-emetic treatment regimens were compared in 357 patients receiving cisplatin therapy (mean dose 81 mg/m2) in this double-blind randomized study. Regimens studied were i) granisetron 1 mg bd orally for 7 days (granisetron alone); ii) gran 1 mg bd orally for 7 days plus prophylactic dexamethasone (12 mg i.v.) on the first day only (gran/dex); iii) metoclopramide (3 mg/kg i.v. loading dose; 4 mg/kg i.v. infusion) plus dex (12 mg i.v.) on the first day followed by met 10 mg orally tds for a further 6 days (met/dex).lld:pubmed
pubmed-article:7993831pubmed:languageenglld:pubmed
pubmed-article:7993831pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7993831pubmed:citationSubsetIMlld:pubmed
pubmed-article:7993831pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7993831pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7993831pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7993831pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7993831pubmed:statusMEDLINElld:pubmed
pubmed-article:7993831pubmed:monthSeplld:pubmed
pubmed-article:7993831pubmed:issn0923-7534lld:pubmed
pubmed-article:7993831pubmed:authorpubmed-author:HeronJ FJFlld:pubmed
pubmed-article:7993831pubmed:authorpubmed-author:CunninghamJJlld:pubmed
pubmed-article:7993831pubmed:authorpubmed-author:GoedhalsLLlld:pubmed
pubmed-article:7993831pubmed:authorpubmed-author:JordaanJ PJPlld:pubmed
pubmed-article:7993831pubmed:authorpubmed-author:CedarEElld:pubmed
pubmed-article:7993831pubmed:issnTypePrintlld:pubmed
pubmed-article:7993831pubmed:volume5lld:pubmed
pubmed-article:7993831pubmed:ownerNLMlld:pubmed
pubmed-article:7993831pubmed:authorsCompleteYlld:pubmed
pubmed-article:7993831pubmed:pagination579-4lld:pubmed
pubmed-article:7993831pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:meshHeadingpubmed-meshheading:7993831-...lld:pubmed
pubmed-article:7993831pubmed:year1994lld:pubmed
pubmed-article:7993831pubmed:articleTitleOral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.lld:pubmed
pubmed-article:7993831pubmed:affiliationCentre François Baclesse, Caen, France.lld:pubmed
pubmed-article:7993831pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7993831pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7993831pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:7993831pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7993831lld:pubmed